Arrhythmia Atrial Fibrillation Circulation 
DAIC
MARCH 31, 2025
arrhythmia yield versus 69.1% in daily-symptom patients, demonstrating that greater symptom frequenc y does not necessarily reflect increased arrhythmia burden. arrhythmia yield versus 69.1% in daily-symptom patients, demonstrating that greater symptom frequenc y does not necessarily reflect increased arrhythmia burden.
DAIC
DECEMBER 29, 2023
Unlike paroxysmal AF, which describes symptoms that last for seven days or fewer, persistent AF is a sustained arrhythmia that lasts for more than a week 1. Circulation. Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent.
DAIC
MARCH 28, 2024
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Food & Drug Administration ( FDA ).
Dr. S. Venkatesan MD
APRIL 28, 2024
When atrial fibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. A fibrillatory wave that occurs at a rate of more than 600 beats per minute can cause fatigue in the long run, leading to atrial dilation.
Circulation
NOVEMBER 29, 2023
Circulation, Ahead of Print. Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation” have been updated with new evidence to guide clinicians.
Circulation
AUGUST 4, 2024
Circulation, Volume 150, Issue 6 , Page 488-503, August 6, 2024. Despite early evidence of an antiarrhythmic role of n-3 PUFA in the prevention of sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-designed randomized trials have largely not shown an antiarrhythmic benefit.
CardiacWire
SEPTEMBER 11, 2024
A JACC study suggests that atrial fibrillation is far more prevalent than many previously thought, estimating that nearly one in 20 American adults have been diagnosed with the disease. That’s far higher than previous estimates, including a pair of JAMA and Circulation studies that estimated nationwide AFib rates of 2.26M and 5.1M
Expert insights. Personalized for you.
52 
Let's personalize your content